Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors

Sponsor
St. Jude Children's Research Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06053268
Collaborator
(none)
50
1
1
24
2.1

Study Details

Study Description

Brief Summary

This study will explore feasibility and acceptability of using a daily mobile mindfulness app to cope with stress. In addition, feasibility of digital health data collection procedures including wrist-worn devices and ecological momentary assessments will be examined.

PRIMARY OBJECTIVES

  • Determine the feasibility and acceptability of completing the 30-day mobile mindfulness program

  • Evaluate the feasibility of digital health data collection procedures to detect autonomic nervous system (ANS) activation associated with stress (e.g., electrodermal activity, pulse rate variability, skin temperature) via wearable devices and self-reported ecological momentary assessments (EMA) among adult survivors of childhood cancer in the SJLIFE cohort

  • Generate preliminary data to estimate the effect size and power needed for an extramurally funded randomized controlled trials (RCT) examining the impact of daily mindfulness mediation on biomarkers of ANS activation, coping, health behaviors, and cardiometabolic outcomes in a cohort of survivors of childhood cancer.

Condition or Disease Intervention/Treatment Phase
  • Device: Headspace
N/A

Detailed Description

Prior to engaging in the intervention participants will complete baseline assessments of stress and coping. Participants will then engage in a daily mindfulness practice via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control. During the first and fourth week of the intervention, participants will complete EMAs assessing mood, current activity, and intervention engagement. Participants will also wear a wrist-worn device to assess biomarkers of stress. At the completion of the intervention participants will complete follow-up assessments related to intervention and data collection procedures feasibility and acceptability as well as coping behaviors and stress.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Oct 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single-arm, within-subject pilot: EmbracePlus smartwatch

Prior to engaging in the intervention participants will complete baseline assessments of stress and coping. Participants will then engage in a daily mindfulness practice via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control. During the first and fourth week of the intervention, participants will complete EMAs assessing mood, current activity, and intervention engagement. Participants will also wear a wrist-worn device to assess biomarkers of stress. At the completion of the intervention participants will complete follow-up assessments related to intervention and data collection procedures feasibility and acceptability as well as coping behaviors and stress.

Device: Headspace
The intervention will be delivered via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control

Outcome Measures

Primary Outcome Measures

  1. Intervention feasibility. [30 days (during intervention]

    Headspace provides user metrics including date/time of meditation sessions, number of sessions completed, average duration of each session, and total meditation minutes overall.

  2. Intervention acceptability [up to 1 week post intervention]]

    Treatment Acceptability and Adherence Scale- Participants will rate on a 0 ("Strongly disagree") to 7 ("Strongly agree") scale regarding their perceptions of acceptability of the mindfulness intervention (10 items).

  3. Data collection feasibility. [up to 1 week post intervention]

    Wearable Technology. EmbracePlus includes on-wrist detection, and this data will be used to evaluate how long and for how many days participants wear the device. EMA. Completion of EMA data will be calculated based on the number of assessments completed

  4. EMA data collection acceptability [up to 1 week post intervention]

    An adapted version of the TAAS was created to evaluate EMA assessment acceptability (7 items). Higher scores are indicative of greater acceptability

Secondary Outcome Measures

  1. Perceived Stress Scale [Baseline and up to 1 week post intervention]

    This measure is a 10-item, widely used and validated assessment of stress and efficacy of managing stress. The Participants are asked to respond to each question on a 5-point Likert scale ranging from 0 (never) to 4 (very often), indicating how often they have felt or thought a certain way within the past month. Scores range from 0 to 40.

  2. Brief Cope inventory is a 28-item, validated assessment measure of positive and negative coping strategies across 14 domains. Participants respond on a 4 point Likert scale how often they have engaged in a particular coping strategy [Baseline and up to 1 week post intervention]

    Digital biomarkers of ANS activation. EmbracePlus (Empatica, Milano, Italy) is a smartwatch engineered to collect physiological biomarkers associated with ANS activation including electrodermal activity (EDA), pulse rate variability, inter-beat interval, respiratory rate, skin temperature, blood volume pulse- each used to develop a stress experience composite score

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Research participant is at least 18 years old at enrollment

  • Research participant is followed by St. Jude Children's Research Hospital (SJCRH)

  • Research participant has a diagnosis history of leukemia or lymphoma

  • Research participant takes part in the St. Jude Lifetime Cohort Study (SJLIFE)

  • Research participant has elevated psychological stress scores of 6 or greater on most recent SJLIFE questionnaire

  • Participant can speak and read English

Exclusion Criteria:
  • Research participant currently engages in mindful stress-reduction practices >2x per week (e.g., tai chi, meditation)

  • Research participant takes psychiatric medications or medications that impact cardiac functioning, beta-blockers, alpha-blockers

  • Research participant wears a pacemaker

  • Research participant has a diagnosis of a congenital heart disease

  • Research participant has no access to a smartphone

  • Research participant has elevated pain interference scores (T≥70)

Contacts and Locations

Locations

Site City State Country Postal Code
1 St. Jude Children's Research Hospital Memphis Tennessee United States 38105

Sponsors and Collaborators

  • St. Jude Children's Research Hospital

Investigators

  • Principal Investigator: Rachel Webster, PhD, St. Jude Children's Research Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier:
NCT06053268
Other Study ID Numbers:
  • MINDHACS
First Posted:
Sep 25, 2023
Last Update Posted:
Sep 25, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes

Study Results

No Results Posted as of Sep 25, 2023